An innovative educational proposal aims to explain the wide range of different approaches that oncologists worldwide use to approach metastatic breast cancer (mBC) care. Targeting the USA, Japan, Spain, Italy, Germany and France, this initiative is based on extensive self-study modules with speaking notes that are translated into the native languages of each targeted country.

The two self-study modules are designed to offer a thorough understanding of the many treatment modalities available.

From conventional methods to cutting-edge innovations, the modules provide insights into BC management optimisation, including the use of antibody-drug conjugates (ADCs), immunotherapy, poly (adenosine diphosphate-ribose) polymerase (parp)-inhibitors and a potential therapeutic algorithm for human epidermal growth factor receptor 2 (HER2)-low breast cancer.

Highlights of the European Society for Medical Oncology Congress 2024 are available for downloading and registration for the programme, which is accredited as continuing medical education, is free of charge.

The learning objectives of the programme are to:

• assess the efficacy and safety of treatment approaches, especially ADCs plus immunotherapy, in the management of patients with mBC, and implications for team-based and shared decision-making globally;

• apply the most recent evidence-based recommendations on the use of ADCs during the management of patients with HER2+, hormone-receptor-positive (HR+), HER2-low and triple-negative BC, based on specific patient and tumour characteristics; and to

• discuss the most recent evidence-based recommendations and guidelines on the role of ADCs, with a focus on safety, in the management of patients with mBC.